Trials / Unknown
UnknownNCT04618328
A Study of ATRA in the Treatment of ITP
A Study of All-trans Retinoic Acid in the Treatment of Immune Thrombocytopenia
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
An open-label, multicenter study to compare the efficacy and safety of ATRA for the treatment of adults with primary immune thrombocytopenia (ITP)
Detailed description
The investigators are undertaking an open-label, single-arm, multicenter trial of adults patients with ITP in China. Patients with treatmant naive ITP were given ATRA treatment. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | all trans retinoic acid | ATRA is given concomitantly at a daily dose of 10 mg twice daily orally for 12 weeks |
Timeline
- Start date
- 2020-11-01
- Primary completion
- 2021-10-01
- Completion
- 2021-10-01
- First posted
- 2020-11-05
- Last updated
- 2020-11-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04618328. Inclusion in this directory is not an endorsement.